Literature DB >> 28686127

Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome.

Wuyang Yang1, Risheng Xu1, Jose L Porras1, Clifford M Takemoto2, Syed Khalid1, Tomas Garzon-Muvdi1, Justin M Caplan1, Geoffrey P Colby1, Alexander L Coon1, Rafael J Tamargo1, Judy Huang1, Edward S Ahn1.   

Abstract

OBJECTIVE Sickle cell disease (SCD) in combination with moyamoya syndrome (MMS) represents a rare complication of SCD, with potentially devastating neurological outcomes. The effectiveness of surgical revascularization in this patient population is currently unclear. The authors' aim was to determine the effectiveness of surgical intervention in their series of SCD-MMS patients by comparing stroke recurrence in those undergoing revascularization and those undergoing conservative transfusion therapy. METHODS The authors performed a retrospective chart review of patients with MMS who were seen at the Johns Hopkins Medical Institution between 1990 and 2013. Pediatric patients (age < 18 years) with confirmed diagnoses of SCD and MMS were included. Intracranial stroke occurrence during the follow-up period was compared between surgically and conservatively managed patients. RESULTS A total of 15 pediatric SCD-MMS patients (28 affected hemispheres) were included in this study, and all were African American. Seven patients (12 hemispheres) were treated with indirect surgical revascularization. The average age at MMS diagnosis was 9.0 ± 4.0 years, and 9 patients (60.0%) were female. Fourteen patients (93.3%) had strokes before diagnosis of MMS, with an average age at first stroke of 6.6 ± 3.9 years. During an average follow-up period of 11.6 years, 4 patients in the conservative treatment group experienced strokes in 5 hemispheres, whereas no patient undergoing the revascularization procedure had any strokes at follow-up (p = 0.029). Three patients experienced immediate postoperative transient ischemic attacks, but all recovered without subsequent strokes. CONCLUSIONS Indirect revascularization is suggested as a safe and effective alternative to the best medical therapy alone in patients with SCD-MMS. High-risk patients managed on a regimen of chronic transfusion should be considered for indirect revascularization to maximize the effect of stroke prevention.

Entities:  

Keywords:  DSA = digital subtraction angiography; EDAMS = encephalo-duro-arterio-myo-synangiosis; EDAS = encephalo-duro-arterio-synangiosis; MMS = moyamoya syndrome; SCD = sickle cell disease; moyamoya syndrome; pediatric; revascularization; sickle cell disease; vascular disorders

Mesh:

Year:  2017        PMID: 28686127     DOI: 10.3171/2017.1.PEDS16576

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  3 in total

Review 1.  Advances in Understanding Ischemic Stroke Physiology and the Impact of Vasculopathy in Children With Sickle Cell Disease.

Authors:  Kristin P Guilliams; Melanie E Fields; Michael M Dowling
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

Review 2.  Juvenile Moyamoya and Craniosynostosis in a Child with Deletion 1p32p31: Expanding the Clinical Spectrum of 1p32p31 Deletion Syndrome and a Review of the Literature.

Authors:  Paolo Prontera; Daniela Rogaia; Amedea Mencarelli; Valentina Ottaviani; Ester Sallicandro; Giorgio Guercini; Susanna Esposito; Anna Bersano; Giuseppe Merla; Gabriela Stangoni
Journal:  Int J Mol Sci       Date:  2017-09-17       Impact factor: 5.923

3.  American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

Authors:  M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad
Journal:  Blood Adv       Date:  2020-04-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.